Taghiloo et al. showed in a murine model of acute myeloid leukemia (AML) that treatment with a dual PI3K/mTOR inhibitor and TLR-7/8 agonist can reduce the expression of PD-L1, Gal-9, and CD155 [43]. This evidence concerns the gene MTOR and acute myeloid leukemia.